Search results
61 Results for 'Artificial Intelligence'
- Technologies (11)
- Collaborations (2)
- Team (0)
- News (36)
- Pages (0)
- Multimedia (11)
- Publications (0)
- Jobs (0)
- Events (1)
Technologies 11
-
NeoSense: Sepsis Detection in Newborns
NeoSense is a new test that uses a tiny sample of saliva instead of blood, powered by advanced single-molecule detection and AI. -
AminoX: Making Better Protein Drugs, Quicker and Cheaper
AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition. -
Ichor: Reversing Aging
Ichor is addressing multiple age-related diseases by identifying genetic interventions that reprogram old cells to a younger state. Therapies based on these interventions could improve survival for cancer patients and long-term cardiovascular and neurological health. -
CogniXense for Rare Disease Drug Discovery
Unravel Biosciences has licensed a Wyss drug discovery platform technology to identify and create drugs to treat complex central nervous system disorders, starting with Rett syndrome. -
CircaVent: A Drug Discovery Platform for Mental Health Conditions
CircaVent is a novel drug discovery platform that combines predictive algorithms, high-throughput preclinical models, and human organoids to identify and test drugs that could treat mental health conditions like bipolar disorder. -
OrbitSeq: A Collaborative Digital Hub for Life Sciences Data
OrbitSeq is a digital platform that empowers life sciences researchers to browse, upload, and analyze datasets, and easily collaborate with each other to bring science closer together and speed up the pace of discovery.
Collaborations 2
-
Wyss AI DataHub
The Wyss Institute’s AI DataHub integrates patient samples, cutting-edge tissue models, and multi-omics technologies to generate rich, translational datasets – accelerating breakthroughs in drug discovery, biomarker development, and beyond through strategic partnerships. -
Biomarker Discovery Laboratory (BDL)
Bridging the diagnostic gap from biomarker discovery to market-ready test kits and instruments through cutting-edge technology development and clinical collaboration.
News 36
Multimedia 11
-
Audio/PodcastJames Collins: Doing Good Science with an Underdog Spirit – The Pulse PodcastJames J. Collins is a founding Core Faculty member at the Wyss Institute and the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT. Jim serves as a director at the MIT Jameel Clinic, a member of the Harvard-MIT Health Sciences & Technology Faculty, and a member of the Broad... -
Video/AnimationCan We Stop Stabbing Babies? – Salivary Diagnostics for Sepsis Screening in the NeonateEvery day, across the neonatal care unit, babies are being stabbed to collect their blood for sepsis tests. Adding to this dismal situation, diagnostics developed to assess sepsis in blood are very inaccurate, leading to the unnecessary prescription of antibiotics. Researchers at the Wyss Institute and Brigham and Women’s Hospital have created a more accurate... -
Video/AnimationFinding a Balance In Bipolar Disorder Through Drug Prediction and Organoid-Based Drug ScreeningCircaVent is a high-throughput drug screening platform that combines predictive algorithms, preclinical models, and human brain organoids to efficiently identify and test drugs that could treat the underlying causes of bipolar disorder. CircaVent is initially focused on addressing the circadian rhythm disruptions that are a common hallmark of BD, and could dramatically speed up the... -
Video/AnimationAtlantic Health: Accelerating Innovation – AI and Drug DiscoveryThe Atlantic’s Health Summit returned to Boston in 2025 for their annual exploration of the urgent issues reshaping the healthcare landscape. The event showcased recent breakthroughs that are redefining medical practices and explored the challenges of scaling innovation and implementing sustainable solutions. Speakers explored early disease detection, novel anesthetics, pain management, AI and drug discovery,... -
Video/AnimationPeter Nguyen: Biology Engineering, Bigfoot Hunting, and Better Climate TechnologyWyss Senior Scientist Peter Nguyen received a B.S. in Biochemistry and B.A. in Philosophy from the University of Texas, his M.Bs. from the Keck Graduate Institute, and his Ph.D. in Biochemistry from Rice University. At the Wyss Institute, Peter currently works on programmable probiotics and freeze-dried cell-free manufacturing technology across multiple platforms. His research interests... -
Video/AnimationUsing deep learning to detect cancerous skin lesionsMelanoma is a very severe cancer that is often diagnosed too late to save patients’ lives, and most people do not regularly visit a dermatologist for skin exams. Early-stage identification of suspicious pigmented lesions (SPLs), ideally by primary care providers, could lead to improved melanoma prognosis. Researchers at the Wyss Institute and MIT have developed...
